245 related articles for article (PubMed ID: 31783169)
1. Low-Dose Adjuvant Cylinder Brachytherapy for Endometrioid Endometrial Cancer.
Alban GM; Buscariollo DL; Cheng T; Pretz J; Krechmer B; Buzurovic I; Singer L; King M; Lee L
Pract Radiat Oncol; 2020; 10(2):95-103. PubMed ID: 31783169
[TBL] [Abstract][Full Text] [Related]
2. A novel low dose fractionation regimen for adjuvant vaginal brachytherapy in early stage endometrioid endometrial cancer.
Townamchai K; Lee L; Viswanathan AN
Gynecol Oncol; 2012 Nov; 127(2):351-5. PubMed ID: 22850411
[TBL] [Abstract][Full Text] [Related]
3. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
4. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
5. Do vaginal recurrence rates differ among adjuvant vaginal brachytherapy regimens in early-stage endometrial cancer?
Ager BJ; Francis SR; Do OA; Huang YJ; Soisson AP; Dodson MK; Werner TL; Sause WT; Grant JD; Gaffney DK
Brachytherapy; 2019; 18(4):453-461. PubMed ID: 31005603
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
7. Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies?
Dohopolski MJ; Horne ZD; Gebhardt BJ; Glaser SM; Edwards RP; Kelley JL; Comerci JT; Olawaiye AB; Courtney-Brooks M; Berger JL; Sukumvanich P; Beriwal S
Brachytherapy; 2018; 17(3):564-570. PubMed ID: 29426745
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma.
Horowitz NS; Peters WA; Smith MR; Drescher CW; Atwood M; Mate TP
Obstet Gynecol; 2002 Feb; 99(2):235-40. PubMed ID: 11814503
[TBL] [Abstract][Full Text] [Related]
9. Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer.
Alektiar KM; McKee A; Venkatraman E; McKee B; Zelefsky MJ; Mychalczak BR; Hoskins WJ; Barakat RR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):707-13. PubMed ID: 12062616
[TBL] [Abstract][Full Text] [Related]
10. Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer.
Jolly S; Vargas C; Kumar T; Weiner S; Brabbins D; Chen P; Floyd W; Martinez AA
Gynecol Oncol; 2005 Jun; 97(3):887-92. PubMed ID: 15943991
[TBL] [Abstract][Full Text] [Related]
11. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
[TBL] [Abstract][Full Text] [Related]
12. Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy.
Kumar VJ; Nin CY; Kuei LY; Tan KH; Yeo R; Lam PY
Int J Gynecol Cancer; 2010 May; 20(4):564-9. PubMed ID: 20686374
[TBL] [Abstract][Full Text] [Related]
13. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.
Barney BM; Petersen IA; Mariani A; Dowdy SC; Bakkum-Gamez JN; Haddock MG
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):109-15. PubMed ID: 22543202
[TBL] [Abstract][Full Text] [Related]
14. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
[TBL] [Abstract][Full Text] [Related]
16. Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma.
Jordan SE; Micaily I; Hernandez E; Ferriss JS; Miyamoto CT; Li S; Micaily B
Brachytherapy; 2017; 16(6):1144-1151. PubMed ID: 28958736
[TBL] [Abstract][Full Text] [Related]
17. Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer.
Townamchai K; Berkowitz R; Bhagwat M; Damato AL; Friesen S; Lee LJ; Matulonis U; O'Farrell D; Viswanathan AN
Gynecol Oncol; 2013 Apr; 129(1):18-21. PubMed ID: 23262378
[TBL] [Abstract][Full Text] [Related]
18. The impact of adjuvant vaginal brachytherapy in women with Stage II uterine endometrioid carcinoma: Results of a National Cancer Database analysis.
Lee JK; Ghanem AI; Modh A; Burmeister C; Mahmoud O; Maxwell GL; Elshaikh MA
Brachytherapy; 2018; 17(2):319-325. PubMed ID: 29174935
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer.
Jeans EB; Breen WG; Mullikin TC; Looker BA; Mariani A; Keeney GL; Haddock MG; Petersen IA
Int J Gynecol Cancer; 2021 Jun; 31(6):859-867. PubMed ID: 33563642
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes using adjuvant pelvic intensity modulated radiation therapy (IMRT) for endometrial carcinoma.
He S; Gill BS; Heron DE; Kelley JL; Sukumvanich P; Olawaiye AB; Edwards RP; Comerci J; Beriwal S
Pract Radiat Oncol; 2017; 7(1):19-25. PubMed ID: 27527897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
